PT934065E - Compostos farmaceuticos - Google Patents

Compostos farmaceuticos

Info

Publication number
PT934065E
PT934065E PT97939667T PT97939667T PT934065E PT 934065 E PT934065 E PT 934065E PT 97939667 T PT97939667 T PT 97939667T PT 97939667 T PT97939667 T PT 97939667T PT 934065 E PT934065 E PT 934065E
Authority
PT
Portugal
Prior art keywords
pharmaceutical compounds
cryptophycin compounds
novel cryptophycin
compounds
disrupting
Prior art date
Application number
PT97939667T
Other languages
English (en)
Inventor
Rima S Al-Awar
William J Ehlhardt
Subbaraju V Gottumukkala
Michael J Martinelli
Eric D Moher
Richard E Moore
John E Munroe
Bryan H Norman
Vinod F Patel
Chuan Shih
John E Toth
Vasudevan Venkatraghavan
James E Ray
Original Assignee
Univ Hawaii
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Hawaii, Univ Wayne State filed Critical Univ Hawaii
Publication of PT934065E publication Critical patent/PT934065E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/12Esters of phosphoric acids with hydroxyaryl compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT97939667T 1996-08-30 1997-08-29 Compostos farmaceuticos PT934065E (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2581696P 1996-08-30 1996-08-30
US3911397P 1997-02-26 1997-02-26
US3953097P 1997-03-03 1997-03-03
US4002997P 1997-03-04 1997-03-04

Publications (1)

Publication Number Publication Date
PT934065E true PT934065E (pt) 2006-10-31

Family

ID=27487441

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97939667T PT934065E (pt) 1996-08-30 1997-08-29 Compostos farmaceuticos

Country Status (19)

Country Link
EP (1) EP0934065B1 (pt)
JP (1) JP4364944B2 (pt)
CN (1) CN100356916C (pt)
AT (1) ATE328592T1 (pt)
AU (1) AU722492B2 (pt)
BR (1) BR9711986A (pt)
CA (1) CA2264063C (pt)
CZ (1) CZ64599A3 (pt)
DE (1) DE69736067T9 (pt)
DK (1) DK0934065T3 (pt)
EA (1) EA001913B1 (pt)
ES (1) ES2267149T3 (pt)
IL (1) IL128610A (pt)
NO (1) NO314454B1 (pt)
PT (1) PT934065E (pt)
SI (1) SI0934065T1 (pt)
TR (1) TR199901104T2 (pt)
WO (1) WO1998008505A1 (pt)
YU (1) YU10899A (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680311B1 (en) 1996-08-30 2004-01-20 Eli Lilly And Company Cryptophycin compounds
AU4253997A (en) * 1996-09-06 1998-03-26 Eli Lilly And Company Process and novel intermediates
BR9712805A (pt) * 1996-09-06 1999-11-23 Lilly Co Eli Processo para a preparação de compostos farmecêuticos
CA2281107A1 (en) * 1997-02-26 1998-09-03 Eli Lilly And Company Tripeptide and tetrapeptide pharmaceutical compounds
EA002547B1 (ru) * 1997-02-26 2002-06-27 Эли Лилли Энд Компани Способ селективного эпоксидирования для получения лекарственных соединений
EP0870506A1 (en) * 1997-04-11 1998-10-14 Eli Lilly And Company Compositions comprising a cryptophycin compound in combination with a synchronizing or activating agent for treating cancer
EP0870510A3 (en) * 1997-04-11 1999-09-15 Eli Lilly And Company Synergistic combination comprising cryptophycin derivatives and microtubule synergizing agents
EP0870501A1 (en) * 1997-04-11 1998-10-14 Eli Lilly And Company Use of specific cryptophycin derivatives for the manufacture of a medicament in the treatment of fungal infections
US6376230B1 (en) 1998-10-16 2002-04-23 Eli Lilly And Company Stereoselective process for producing intermediates of cryptophycins
US6103913A (en) * 1998-10-16 2000-08-15 Eli Lilly And Company Process for preparing enollactone derivatives
US6372936B1 (en) * 1999-06-09 2002-04-16 Eli Lilly And Company Optical resolution of aminoisobobutyric acid
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6747021B2 (en) 2000-10-02 2004-06-08 Eli Lilly And Company Cryptophycin compound
ATE452896T1 (de) 2002-03-12 2010-01-15 Bristol Myers Squibb Co C3-cyanoepothilonderivate
CA2640013A1 (en) * 2006-02-09 2007-08-16 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
FR2947269B1 (fr) * 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
AU2011319685B2 (en) * 2010-10-22 2016-02-04 Le Centre National De La Recherche Scientifique Pochoxime conjugates useful for the treatment of HSP90 related pathologies
IT201600108581A1 (it) * 2016-10-27 2018-04-27 Navid Sobhani NUOVE E PIU' POTENTI MOLECOLE PER IL TRATTAMENTO E LA DIAGNOSI DI TUMORI NEUROENDOCRINI (NETs) E DELLE CELLULE STAMINALI DEI NETs
UY37728A (es) * 2017-05-10 2019-01-02 Sanofi Sa Nuevos enlazantes peptídicos y conjugados de criptoficina, su preparación y su uso terapéutico
CN114651000A (zh) * 2019-09-30 2022-06-21 密歇根大学董事会 念珠藻素抗癌剂的生物催化合成

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946835A (en) * 1988-07-15 1990-08-07 Merck & Co., Inc. Antifungal fermentation product and method
US4845085A (en) * 1988-08-09 1989-07-04 Merck & Co., Inc. Antifungal agent
US4845086A (en) * 1988-08-09 1989-07-04 Merck & Co., Inc. Antifungal agent
US5194605A (en) * 1989-12-08 1993-03-16 Merck & Co., Inc. Cyclic renin inhibitors containing 2-substituted (3S,4S)-4-amino-5-cyclohexyl-3-hydroxy pentanoic acid, 2-substituted (3S,4S)-5-cyclohexyl-3,4-di-hydroxy pentanoic acid or 2-substituted (4S,5S)-5-amino-6-cyclohexyl-4-hydroxyhexanoic acid or its analogs
DE69427706T2 (de) * 1993-12-21 2001-10-25 University Of Hawaii, Honolulu Cryptophycine
US5952298A (en) * 1993-12-21 1999-09-14 The University Of Hawaii Cryptophycins
TJ347B (en) * 1995-03-07 2002-10-06 Univ Hawaii Cryptophicin compounds pharmacentical composition method to inhibit the proliteration of cells and and method to treat neoplasia
EP0850316A4 (en) * 1995-08-30 2000-08-23 Univ Hawaii CRYPTOPHYCINE, OBTAINED FROM ABBERANTER BIOSYNTHESIS
ES2194129T3 (es) * 1995-12-22 2003-11-16 Univ Hawaii Compuestos farmaceuticos.
ES2156338T3 (es) * 1996-02-27 2001-06-16 Lilly Co Eli Derivados de criptoficina y su uso como agentes antimicrotubulos.

Also Published As

Publication number Publication date
EP0934065A4 (en) 2000-10-11
JP2002514175A (ja) 2002-05-14
NO314454B1 (no) 2003-03-24
IL128610A0 (en) 2001-01-28
ATE328592T1 (de) 2006-06-15
NO990833L (no) 1999-04-26
JP4364944B2 (ja) 2009-11-18
AU722492B2 (en) 2000-08-03
DK0934065T3 (da) 2006-10-09
ES2267149T3 (es) 2007-03-01
CZ64599A3 (cs) 1999-10-13
WO1998008505A1 (en) 1998-03-05
CN100356916C (zh) 2007-12-26
NO990833D0 (no) 1999-02-22
CN1233957A (zh) 1999-11-03
YU10899A (sh) 2002-03-18
AU4170197A (en) 1998-03-19
EA199900246A1 (ru) 1999-10-28
DE69736067D1 (en) 2006-07-20
HK1025036A1 (en) 2000-11-03
BR9711986A (pt) 1999-08-24
CA2264063A1 (en) 1998-03-05
CA2264063C (en) 2007-03-13
EP0934065A1 (en) 1999-08-11
IL128610A (en) 2004-07-25
DE69736067T9 (de) 2007-10-31
DE69736067T2 (de) 2007-05-10
TR199901104T2 (xx) 1999-07-21
WO1998008505A8 (en) 1999-08-12
EP0934065B1 (en) 2006-06-07
EA001913B1 (ru) 2001-10-22
SI0934065T1 (sl) 2007-02-28

Similar Documents

Publication Publication Date Title
BR9711986A (pt) Compostos farmac-uticos
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
CY1118334T1 (el) Χρηση δαπτομυκινης
AP1697A (en) Azabicycloalkanes as CCR5 modulators.
PT1200412E (pt) Agentes anti-proliferativos de imidazole
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
PL328858A1 (en) Immunogenous peptides
DE60239707D1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
BR0109703A (pt) Derivados de piperazina
TR200101103T2 (tr) CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar
TNSN03060A1 (en) A combination comprising combretastatin and anticancer agents
DE69729183D1 (de) Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
PT1001792E (pt) Utilizacao de compostos de sais e de complexos de vanadio aceites fisiologicamente
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DE69626544T2 (de) Arzneistoffe
IS6087A (is) N-(2-fenýl-4-amínó-bútýl)-1-naftamíð sem virka á móti taugakínín-1 viðtaka
BR9608255A (pt) Sistema terapéutico transdérmico (stt) para a administração de testosterona
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények
SE0004827D0 (sv) Therapeutic compounds
MX9801604A (es) Compuestos farmaceuticos.
SE9803623D0 (sv) New therapeutic application